Abstract Title:

Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study.

Abstract Source:

Dermatology. 2007 ;214(4):325-7. PMID: 17460404

Abstract Author(s):

Anabelle Brocard, Anne-Chantal Knol, Amir Khammari, Brigitte Dréno

Article Affiliation:

Anabelle Brocard

Abstract:

BACKGROUND: Hidradenitis suppurativa (Verneuil's disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective.

OBJECTIVE: We discuss a new therapeutic approach based on zinc salts.

METHODS: We performed a pilot study on 22 patients, mainly from grade I or II in Hurley's classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc capsule).

RESULTS: We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal.

CONCLUSION: Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.